Skip to main content

MAnufacturing of TUmour-REactive Natural Killer cells

Objective

"This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products (""ATMPs""), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine.
In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors (""CAR"") and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors (""checkpoint inhibitors"") and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials.
"

Field of science

  • /natural sciences/biological sciences/cell biology
  • /social sciences/economics and business
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-MSCA-ITN-2017
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

MEDIZINISCHE HOCHSCHULE HANNOVER
Address
Carl-neuberg-strasse 1
30625 Hannover
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 249 216,48

Participants (12)

OSLO UNIVERSITETSSYKEHUS HF
Norway
EU contribution
€ 286 275,24
Address
Kirkeveien 166 Tarnbygget
0450 Oslo
Activity type
Higher or Secondary Education Establishments
UNIVERSITAT BASEL
Switzerland
EU contribution
€ 265 226,76
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments
IRCCS OSPEDALE POLICLINICO SAN MARTINO
Italy
EU contribution
€ 258 061,32
Address
Largo Rosanna Benzi 10
16132 Genova
Activity type
Research Organisations
INSTITUT PASTEUR
France
EU contribution
€ 262 875,60
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 249 216,48
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
UNIVERSIDAD POMPEU FABRA
Spain
EU contribution
€ 247 872,96
Address
Placa De La Merce, 10-12
08002 Barcelona
Activity type
Higher or Secondary Education Establishments
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
EU contribution
€ 260 300,52
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 255 934,08
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
INNATE PHARMA
France
EU contribution
€ 262 875,60
Address
Avenue De Luminy 117
13009 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MILTENYI BIOTEC GMBH
Germany
EU contribution
€ 249 216,48
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GLYCOSTEM-THERAPEUTICS B.V.
Netherlands
EU contribution
€ 255 374,28
Address
Kloosterstraat 9 Kamer Re 1134
5349 AB Oss
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 249 216,48
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations